Es gibt sehr wenige neue Molek�le, sehr wenige neue Ideen und beinahe nichts, das hoffen lie�e, die medikament�se Behandlung psychischer Erkrankungen zu transformieren. Aufgrund mangelnder Erfolge ziehen sich mehrere Pharmaunternehmen aus dem Gesch�ft zur�ck.
Broad Review of FDA Trials Suggests Antidepressants Only Marginally Better than Placebo
„We found that out of the 4041 patients initially started on the SSRI [selective serotonin reuptake inhibitor] citalopram in the STAR*D study, and after 4 trials, only 108 patients had a remission and did not either have a relapse and/or dropped out by the end of 12 months of continuing care,“ lead study author Ed Pigott, PhD, a psychologist with NeuroAdvantage LLC in Clarksville, Maryland.
„In other words, if you’re trying to look at sustained benefit, you’re only looking at 2.7%, which is a pretty jaw-dropping number,“ added Dr. Pigott.